Randomized comparative study of omeprazole and famotidine in reflux esophagitis

J Gastroenterol Hepatol. 2002 Sep;17(9):955-9. doi: 10.1046/j.1440-1746.2002.02785.x.

Abstract

Background: Although proton pump inhibitors (PPI) and H2-receptor antagonists (H2-RA) are routinely used in the treatment of reflux esophagitis (RE), no consensus has been reached yet as to whether the first-choice drug should be PPI or H2-RA. In this study, the effects of omeprazole (OMP) and famotidine (FAM) on RE have been examined in a randomized comparative study.

Methods: Protocols of OMP 20 mg once daily or FAM 20 mg twice daily for 8 weeks were allocated to 56 cases with RE at random, using an envelope randomization method. Their efficacy in achieving healing was examined endoscopically and a relief from subjective symptoms was compared.

Results: Patient's background such as sex, age, recurrence, hiatal hernia, smoking and drinking habits, and complications, and the severity of esophagitis at the time of enrolment were not significantly different between the two groups. Healing in the OMP group and the FAM group was observed in 72 and 32% (P = 0.025) of patients at week 4 and 95 and 53% (P = 0.003) of patients at week 8, respectively. Subjective symptoms were relieved more frequently in the OMP group (at week 2, 67% compared with 29%, P = 0.005; at week 4, 95% compared with 55%, P = 0.009), but this superiority was not significant at week 8 (94% compared with 65%, P = 0.085). No serious adverse events occurred.

Conclusions: Omeprazole provided quicker healing and a greater relief from subjective symptoms than did FAM in the treatment of RE, and was considered more suitable as a first-choice drug.

Publication types

  • Clinical Trial
  • Comparative Study
  • Evaluation Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Drug Evaluation
  • Enzyme Inhibitors / therapeutic use*
  • Esophagitis, Peptic / drug therapy*
  • Esophagoscopy
  • Famotidine / therapeutic use*
  • Female
  • Gastroesophageal Reflux / drug therapy*
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Prospective Studies
  • Random Allocation
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Histamine H2 Antagonists
  • Famotidine
  • Omeprazole